Dominic D'Agostino

And with Alzheimer's disease, there's like vascular dementia.

It could be a blood flow problem.

It could be excess glutamate problem.

It could be a number of different things that are amenable to being reversed or mitigated through ketone metabolic therapies.

Yeah, I think it's going to be huge.

And I don't think they've done this yet, is that inclusion criteria should be patients that present with remarkable glucose hypometabolism.

So I think that's really an important key.

There's people who have brains that are chock full of amyloid, are completely sharp and are completely normal.

The amyloid hypothesis has a lot of baggage with it.

So I think tau, amyloid and tau,

We have PTAL that we can look at, but there's other things in the pipeline.

I think the P75 receptor agonist or amplifier looks pretty promising.

Those studies are ongoing.

And then for prevention, I think some of these things, the antibodies do have

applications, but they also come with a lot of baggage with not only the cost and accessibility, but cerebral hemorrhage, something they have to consider.

So the low-hanging fruit would be dietary or more likely with this population, a ketone metabolic therapy intervention that could be a ketogenic formula that could also have a number of different cofactors and other things.

There's lactate, there's creatine monohydrate,

there's alpha-ketoglutarate.

And this is the problem with funding agencies.

They don't want to fund a formula.